Jon Scott Jacobsen
Corporate Officer/Principal at ACLARIS THERAPEUTICS, INC.
Profile
Jon Scott Jacobsen is currently working as Chemistry Director at Aclaris Life Sciences, Inc. and as Senior Vice President-Chemistry at Aclaris Therapeutics, Inc. He previously worked as Director-Chemistry Department & Senior Scientist at Pfizer Inc. He completed his undergraduate degree from Harvey Mudd College and his doctorate degree from the University of California, Irvine.
Jon Scott Jacobsen active positions
Companies | Position | Start |
---|---|---|
ACLARIS THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Aclaris Life Sciences, Inc.
Aclaris Life Sciences, Inc. Medical/Nursing ServicesHealth Services Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO. | Corporate Officer/Principal | - |
Former positions of Jon Scott Jacobsen
Companies | Position | End |
---|---|---|
PFIZER, INC. | Corporate Officer/Principal | - |
Training of Jon Scott Jacobsen
Harvey Mudd College | Undergraduate Degree |
University of California, Irvine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
PFIZER, INC. | Health Technology |
ACLARIS THERAPEUTICS, INC. | Health Technology |
Private companies | 1 |
---|---|
Aclaris Life Sciences, Inc.
Aclaris Life Sciences, Inc. Medical/Nursing ServicesHealth Services Aclaris Life Sciences, Inc. operates as a technology-based company which focuses on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases. It also engages in design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis in modulations of chronic inflammation. The company was founded by Joseph B. Monahan, Gabriel Mbalaviele and Shaun R. Selness in 2010 and is headquartered in St. Louis, MO. | Health Services |
- Stock Market
- Insiders
- Jon Scott Jacobsen